Author:
de Bekker-Grob Esther W.,Berlin Conny,Levitan Bennett,Raza Karim,Christoforidi Kalliopi,Cleemput Irina,Pelouchova Jana,Enzmann Harald,Cook Nigel,Hansson Mats G.
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49:929–39.
2. Smith MY, Hammad TA, Metcalf M, et al. Patient engagement at a tipping point—the need for cultural change across patient, sponsor, and regulator stakeholders: insights from the DIA conference, “Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products”. Ther Innov Regul Sci. 2016;50:546–53.
3. Medical Device Innovation Consortium (MDIC) Patient-Centered Benefit-Risk Project report.
http://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Web.pdf
. Accessed 20 Feb 2017.
4. The IMI PREFER project.
http://www.imi-prefer.eu/
. Accessed 20 Feb 2017.
5. US Department of Health and Human Services. Food and Drug Administration. Center for Devices and Radiological Health. Center for Biologics Evaluation and Research. Patient Preference Information—Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labelling. Guidance for industry, food and Drug Administration Staff, and Other Stakeholders. 24 August 2016.
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM446680.pdf
. Accessed 20 Feb 2017.
Cited by
95 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献